Jamjoom Pharmaceuticals Factory Co.

Last Updated:
  • 145.80 SAR
  • -0.20
  • -0.14%
شركة مصنع جمجوم للأدوية
جمجوم فارما
Symbol : 4015
ISIN : SA15QGU1UNH6
52-Week Range : 100.20 - 158.20
Turnover Ratio : 1.73
Market : Saudi Exchange
Sector : Pharma, Biotech & Life Science
Industry : Pharmaceuticals and Biotechnology Research & Development
Sub-Industry :

Basic Information

  • Activity :
    Jamjoom Pharmaceuticals Factory Co. (known as: JAMJOOM PHARMA) is a public company, listed on Saudi Exchange “Tadawul” (TDWL) since June 2023. JAMJOOM PHARMA operats within the pharmaceuticals Research...
  • Industry Group :
    pharmaceuticals Research and Biotechnology
  • Sub-Industry :
  • ISIN :
    SA15QGU1UNH6
  • Contact Person :
  • Established On:
    22-Sep-1994
  • Stock Listing On :
    20-Jun-2023
  • No of Employees :
    1,370 Employees as of 2023
  • Outstanding Shares :
    70,000,000
  • Free Float Shares :
  • Par Value :
  • Paid Capital :
  • Market Cap :
  • Authorized Capital :

Indices Membership

Action Date Index Provider
Join 2023 Pharma, Biotech & Life Science Saudi Exchange Co
Join 2023 Tadawul All Share Index (TASI) Saudi Exchange Co
Jamjoom Pharmaceuticals Factory Co.
Jeddah Industrial City, Phase Five, Plot Three M A, PO Box 006267, Jeddah 21442, Kingdom Saudi Arabia
T : +966 12 6140099
F : +966 12 6140088
www.jamjoompharma.com
ir@jamjoompharma.com

Management

Title Name As Of
Chairman: Mahmoud Jamjoom 2022
CEO: Tarek Hosni 2021
Deputy Chairman: Ahmed Jamjoom 2022
Board Member: Georges Schorderet 2023
Noor Sheriff 2022
Mohammed Jamjoom 2022
Alaa Jamjoom 2022
Faris Al Ghannam 2022
Yousuf Jamjoom 2022
Michel Le Bars 2022

Reports

Date Title File
2024 JAMJOOM PHARMA Quarterly Financials Report Q1 2024
2024 Jamjoom Pharma reports 22.0% Net Profit growth to SAR 103.0 million in 1Q 2024
2024 JAMJOOM PHARMA Annual Financials Report 2023
2024 Jamjoom Pharma reports 71% net profit growth to SAR292.4 million in 2023
2023 JAMJOOM PHARMA Quarterly Financials Report Q3 2023
2023 Jamjoom Pharma reports 78% net profit growth to SAR 248 million in 9M 2023
2023 JAMJOOM PHARMA Quarterly Financials Report Q2 2023
2023 Jamjoom Pharma reports 81.7% net profit growth to SAR 170.7 million in 1H 2023
2023 JAMJOOM PHARMA Quarterly Financials Report Q1 2023
2023 Jamjoom Pharma achieves highest ever quarterly sales at SAR 302 million reflecting a 23.9% increase YoY, Net Profit increases by 94%
2023 Jamjoom Pharmaceuticals Factory Company Announces Results of The Subscription Period for Individual Investors
Check our coverage for